Houston, TX (August 6, 2019) – Procyrion, Inc., a clinical-stage medical device company developing the Aortix™ system, a percutaneous blood pump initially targeted for treating patients with heart failure and worsening kidney function (cardiorenal syndrome), announced the appointment of Av Edidin, Ph.D., as Senior Vice President of Development and Manufacturing. In this role, Edidin will lead and oversee product development, manufacturing operations, and the quality system in support of the company’s upcoming clinical studies and future commercialization. Edidin brings to Procyrion more than 25 years of experience as a global medical device leader, with previous leadership in the development and commercial introduction of devices in the long bone orthopedic, spinal fixation and ablation, and catheter instrumentation areas.
“Av brings a depth of experience that will be invaluable as we have now transitioned from the design phase to the verification and validation phase in preparation of our upcoming clinical studies of the Aortix system for the treatment of in-hospital cardiorenal patients,” said Eric S. Fain, M.D., president and chief executive officer of Procyrion. “Av has an extensive career in bringing products from research to production and into widespread clinical and commercial use and we are very pleased that he has joined the Procyrion leadership team.”
“In my career I have been fortunate to participate in bringing revolutionary early-stage products to commercialization,” noted Edidin. “Aortix is precisely such a technology and I am excited to join Procyrion and look forward to working with the team to bring the Aortix system into clinical studies and demonstrate the clinical benefits in cardiorenal patients.”
Edidin served as Chief Scientific Officer of Relievant Medsystems, Inc., managing the company’s technology and intellectual property for intraosseous nerve ablation technology. Previously he served as Vice President, Science and Technology in Medtronic’s Spinal and Biological Division, held the position of Vice President, Research and Development at Kyphon, Inc. and was Principal Research Scientist at Stryker Orthopaedics. He is named on over 15 U.S. and foreign patents.
Edidin received his B.S. in Mechanical and Aerospace Engineering and his Ph.D. in Biomedical Engineering from Cornell University.
Houston-based medical device firm Procyrion, Inc. is developing the first catheter-deployed, intra-aortic pump initially for use in cardiorenal syndrome patients. The device is designed to rest the heart by reducing afterload while simultaneously improving blood flow to vital organs. This groundbreaking cardiology tool, conceived by cardiologist Dr. Reynolds M. Delgado, III, medical director of Mechanical Support Devices in Heart Failure at the Texas Heart Institute, and launched at Fannin Innovation Studio, is being developed to provide a minimally invasive treatment option for millions of chronic heart failure patients.